4,275
Views
22
CrossRef citations to date
0
Altmetric
Commentary

COVID-19 vaccination passport: prospects, scientific feasibility, and ethical concerns

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 4108-4111 | Received 14 May 2021, Accepted 01 Jul 2021, Published online: 22 Jul 2021

ABSTRACT

A vaccination passport (also known as “vaccination certificate,” “immunization passport,” or “digital health pass”) is a document that provides proof of vaccination and certifies that the holder is protected from illness. It is a more reliable and practical substitute for immunity passports since COVID-19 vaccination is considered a better correlate of protection. Vaccination passport can be considered as a tool offering the holder the privilege of traveling freely within countries without any restrictions. The majority of the countries that are dependent on travel and tourism have exhibited a positive inclination toward implementing COVID-19 vaccination passports, while others have a mixed opinion. The successful implementation of vaccination passports will be a complex task for the policymakers as it requires addressing several ethical, legal, and data security concerns outlined in this article. However, vaccination passports can offer economic and health benefits that will allow the gradual recovery of the economy.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in Wuhan, China got rapidly spread across the international borders mainly through air travel.Citation1 The efficient human-to-human transmission of SARS-CoV-2 further challenged our capacity to control this ongoing pandemic.Citation2 The successful rollout of vaccines for coronavirus disease 2019 (COVID-19) has been followed by a global effort to achieve herd immunity. As of June 11, 2021, Israel has fully vaccinated 59% of its population, while the percentage of people vaccinated is 50% in Bahrain, 47% in Chile, 43% in the United Kingdom, 42% in the United States, and 23% in Italy (https://ourworldindata.org/covid-vaccinations).

The concept of “vaccination passport” (also known as “vaccination certificate,” “immunization passport,” or “digital health pass”) is gaining the attention of policymakers and has become a hot topic of debate. A vaccination passport is a document that provides proof of vaccination and certifies that the holder is protected from illness, and therefore, cannot act as a source of infection for othersCitation3,Citation4 and can be allowed to resume routine activities that involve social interactions and travel (both domestic and international) without substantially contributing to the transmission of SARS-CoV-2 within the community.Citation4,Citation5 The implementation of vaccination passports will help us return to a pre-pandemic status where there are no restrictions on global travel and trade.Citation5

Immunity passport or vaccination passport?

The immunity passport (also termed as “immunity license” or “immunity certificate”) is different from a vaccination passport as it provides documentation of the previous infection.Citation6 It has several practical limitations, such as the high cost of testing and susceptibility to reinfection.Citation7 Moreover, our limited understanding of how long does immunity lasts following SARS-CoV-2 infection makes immunity passports unreliable.Citation6 Vaccination passports would hence be a more reliable and practical substitute since vaccination is considered a better correlate of protection.Citation7 However, the emergence of novel SARS-CoV-2 variants (especially variant of concern) can affect the neutralizing potential of vaccine-elicited antibodies resulting in mild-to-substantial loss of efficacy.Citation8 According to the Centers for Disease Control and Prevention (https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html#Concern), variant of concern is “a variant for which there is evidence of an increase in transmissibility, more severe disease (e.g., increased hospitalizations or deaths), a significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures.”

Several countries and agencies have already started implementing vaccination passports in an effort to eliminate domestic and international travel restrictions (); travelers with vaccination passports will be exempted from testing and quarantine requirements. However, there is a lack of understanding on the impact of vaccination on the transmission of SARS-CoV-2.Citation4 The two-dose regimen of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine conferred 95% protection against infection in individuals that are 16 years of age or older.Citation9 Analysis of the real-world dataset confirmed that the inoculation with mRNA COVID-19 vaccine (BNT162b2) substantially reduced the viral load when the vaccinated individuals got infected 12–37 days after the first dose of vaccine.Citation10 The findings give a hint on the role played by vaccines in lowering infectiousness. Vaccination can help to protect the susceptible population from both symptomatic and asymptomatic SARS-CoV-2 infection, thereby reducing the transmission of the virus within the population.Citation11,Citation12 Although preliminary findings indicate that vaccination can help reduce transmission either by lowering the viral load during post-vaccination infections or by preventing asymptomatic and clinical infections, further studies are required to confirm the findings.Citation4,Citation13 In addition to that, the ability of a vaccine to limit disease transmission will also depend upon the age and immune status of the individual, the number of doses and type of vaccine used, the interval since vaccination, and the circulating variants, transmission intensity, and superspreading events at the country of origin and destination.Citation8,Citation14,Citation15

Table 1. Major COVID-19 vaccination passport/certificate initiatives (arranged according to the alphabetical order)

Which vaccines should be considered?

The certification of COVID-19 vaccines varies across countries. Therefore, it will be challenging to establish a universal system for approving vaccines due to vaccine nationalism. The available COVID-19 vaccines also differ extensively across the globe due to the lack of equitable access.Citation16,Citation17 India has initiated a mass vaccination campaign using Covaxin, the indigenously developed inactivated COVID-19 vaccine.Citation18 However, Covaxin is approved for emergency use in very few countries. The growing number of vaccine candidates along with the political concerns, will further add to the complexity of approving vaccines across different jurisdictions. China has recently altered its visa policy to allow foreigners who have taken Chinese-made COVID-19 vaccines to enter the country.Citation19 The move to prioritize domestic COVID-19 vaccines over those approved by the World Health Organization (WHO) has resulted in the emergence of geopolitical vaccine silos. The world nations will be divided into different groups (silos) based on vaccine nationalism rather than medical necessity. This will have a direct impact on several countries as they will be forced to approve Chinese vaccines that have lower efficacy.Citation20 If other nations adopt a similar strategy, it might trigger a chain reaction and could leave the world in vaccine-based silos. Such a move will have a direct impact on the collective effort to counter the ongoing pandemic.

Data elements for vaccination passport

The vaccination passport should be accessible to all by making it affordable and portable. It should contain three key sections, each corresponding to a part of the core dataset: header, data elements for each vaccination event, and metadata.Citation20 The header section should contain data elements such as name, sex, date of birth, and a unique identifier that can be used to identify the vaccinated individual securely.Citation20 The data elements for each vaccination event should include vaccine brand or trade name, vaccine category (mRNA, inactivated, or other), vaccine manufacturer/market authorization holder, batch number, date of vaccination, dose number, administering center, country of vaccination, the signature of health worker (for paper vaccination passports), identification of health worker (for digital vaccination passports), disease or agent targeted (COVID-19 or SARS-CoV-2), and due date of next dose. The metadata will contain additional data elements that are linked to the passport but are not visible and accessible to the holder.Citation20 Vaccination passports can take the form of paper or digital records. Since “paper only” vaccination passports can be easily falsified, “digital twin” passports are better substitutes as they can be verified and validated using Quick Response (QR) code, barcode, or other reliable 2D data matrices. It can also be transformed into digital formats (pdf or jpeg format) and stored on a smartphone application or a cloud-based server.

Ethical concerns

Unless and until there is equitable access to COVID-19 vaccines across the globe, supply scarcity can unfairly exclude individuals who cannot access vaccines. However, once everyone has access to vaccines, there will be a strong ethical justification for implementing vaccination passports as it creates a safer environment to work, travel, and perform other routine activities.Citation5 Limiting the validity of vaccination passports to certain vaccines can further exacerbate inequities based on access to these particular vaccines.Citation5,Citation19 It is evident that the implementation of vaccination passports as a condition of travel would directly impact low- and middle-income countries as they lack adequate access to vaccine doses to vaccinate their whole population.Citation5,Citation21 Majority of the countries that have not initiated COVID-19 vaccination campaigns are sub-Saharan African nations. Furthermore, the existing race-based health disparities will pose a persistent challenge in attaining global vaccination coverage.Citation21 In addition, the historic distrust exhibited by certain minorities for their health system should not disqualify them from social and economic opportunities associated with vaccination passports.Citation5

Challenges

Several nations and agencies have already started using digital COVID-19 vaccination passports for domestic and international travel using the existing framework and infrastructure.Citation3 The expiration date of the issued COVID-19 vaccination passport should correspond to the duration of protection conferred by the specific vaccine. However, emerging SARS-CoV-2 variants will have an impact on the duration of the efficacy of vaccines that are currently approved for use. Therefore, provision to revoke/renew the passports has to be provided in situations where a novel variant has emerged that can escape the vaccine-induced antibodies. Measures have to be taken to prevent the forgery of vaccination passports.Citation21 The authenticity of the digital passport can be cryptographically verified using the in-built QR code, and the interested party can access the data and metadata linked with the passport directly from the online server.Citation20 Although personal data security is a major concern associated with using digital passports, the data can be safely encrypted similar to that used routinely for financial and other sensitive transactions.Citation3 The platform used for generating COVID-19 vaccination passports has to be internationally standardized and should be based on interoperable technologies to facilitate easy verification of credentials. Although the development of such an interoperable technology seems to be an easy task, the major issue will be to obtain clearance from the corresponding national competent authorities for its use.

Conclusion

Although the universal implementation of the COVID-19 vaccine passport requires overcoming multiple hurdles, it is clear that vaccine passports are essential for the long-term management of COVID-19. The majority of the countries that are dependent on travel and tourism have exhibited a positive inclination toward implementing COVID-19 vaccination passports, while others have a mixed opinion. However, it is unethical to force an individual to get vaccinated and to ban an unvaccinated traveler from entering a country. Therefore, a vaccine passport should be considered as a tool offering the holder the privilege of traveling freely within countries without any restrictions. Unvaccinated travelers will be subjected to restrictions upon arrival in a country and should undergo mandatory quarantine and RT-PCR testing as per the local requirements. The successful implementation of vaccination passports will be a complex task as it requires addressing ethical, legal, and data security concerns outlined in this article. However, vaccination passports can offer economic and health benefits until herd immunity is achieved, thereby allowing the gradual recovery of the economy.

Author contributions

KS conceptualized the manuscript; KS wrote the first draft with input from RT, KD, AAR, and SA; all authors contributed to revisions and approved the final manuscript.

Disclosure of potential conflicts of interest

All authors declare that there exist no commercial or financial relationships that could, in any way, lead to a potential conflict of interest.

Additional information

Funding

The authors received no funding in relation to this article.

References

  • Sharun K, Tiwari R, Natesan S, Yatoo MI, Malik YS, Dhama K. International travel during the COVID-19 pandemic: implications and risks associated with ‘travel bubbles J Travel Med. 2020 Dec 23;27(8):taaa184. doi:10.1093/jtm/taaa184. PMID: 33009813; PMCID: PMC7665670.
  • Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, Singh KP, Chaicumpa W, Bonilla-Aldana DK, Rodriguez-Morales AJ. Coronavirus Disease 2019-COVID-19. Clin Microbiol Rev. 2020 Jun 24;33(4):e00028–20. doi:10.1128/CMR.00028-20. PMID: 32580969; PMCID: PMC7405836.
  • Dye C, Mills MC. COVID-19 vaccination passports. Science. 2021 Mar 19;371(6535):1184. doi:10.1126/science.abi5245. PMID: 33737463.
  • The Lancet Microbe.Vaccine certificates: does the end justify the means? Lancet Microbe. 2021 Apr;2(4):e130. doi:10.1016/S2666-5247(21)00067-7. Epub 2021 Mar 30. PMID: 33817675; PMCID: PMC8009611.
  • Gostin LO, Cohen IG, Shaw J. Digital health passes in the age of COVID-19: are “vaccine passports” lawful and ethical? JAMA. 2021 Apr 7;325:1933. doi:10.1001/jama.2021.5283. Epub ahead of print. PMID: 33825831.
  • Chen LH, Freedman DO, Visser LG. COVID-19 immunity passport to ease travel restrictions? J Travel Med. 2020 Aug 20;27(5):taaa085. doi:10.1093/jtm/taaa085. PMID: 32463093; PMCID: PMC7313786.
  • Schlagenhauf P, Patel D, Rodriguez-Morales AJ, Gautret P, Grobusch MP, Leder K. Variants, vaccines and vaccination passports: challenges and chances for travel medicine in 2021. Travel Med Infect Dis. 2021 Mar-Apr;40:101996. doi:10.1016/j.tmaid.2021.101996. Epub 2021 Feb 23. PMID: 33631338; PMCID: PMC7899929.
  • Sharun K, Tiwari R, Dhama K, Emran TB, Rabaan AA, Mutair AA. Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies. Hum Vaccin Immunother. 2021:1–4. doi:10.1080/21645515.2021.1923350. (In Press).
  • Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–15. doi:10.1056/NEJMoa2034577. Epub 2020 Dec 10. PMID: 33301246; PMCID: PMC7745181.
  • Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, Wolf T, Nadler V, Ben-Tov A, Kuint J, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021 Mar 29;27:790–92. doi:10.1038/s41591-021-01316-7. Epub ahead of print. PMID: 33782619.
  • Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J, Gillson N, Atti A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021 May 8;397(10286):1725–35. doi:10.1016/S0140-6736(21)00790-X. Epub 2021 Apr 23. PMID: 33901423; PMCID: PMC8064668.
  • Leshem E, Lopman BA. Population immunity and vaccine protection against infection. Lancet. 2021 May 8;397(10286):1685–87. doi:10.1016/S0140-6736(21)00870-9. Epub 2021 Apr 23. PMID: 33901422; PMCID: PMC8064666.
  • Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan AJ, Niesen MJM, O'Horo JC, Virk A, Swift MD, Badley AD, et al. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med (NY). 2021 Jun 29. doi:10.1016/j.medj.2021.06.007. Epub ahead of print. PMID: 34223401; PMCID: PMC8238652.
  • Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021 Feb;21(2):e26–e35. doi:10.1016/S1473-3099(20)30773-8. Epub 2020 Oct 27. PMID: 33125914; PMCID: PMC7837315.
  • Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 Mar 6;397(10277):881–91. doi:10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19. PMID: 33617777; PMCID: PMC7894131.
  • Sharun K, Dhama K. COVID-19 vaccine diplomacy and equitable access to vaccines amid ongoing pandemic. Arch Med Res. 2021 Apr 23:S0188-4409(21)00112–0. doi:10.1016/j.arcmed.2021.04.006. Epub ahead of print. PMID: 33941393; PMCID: PMC8062433.
  • Sharun K, Singh R, Dhama K. Oxford-AstraZeneca COVID-19 vaccine (AZD1222) is ideal for resource-constrained low- and middle-income countries. Ann Med Surg (Lond). 2021 May;65:102264 . doi:10.1016/j.amsu.2021.102264. Epub 2021 Mar 31. PMID: 33815783; PMCID: PMC8010342.
  • Sharun K, Dhama K. India’s role in COVID-19 vaccine diplomacy. J Travel Med. 2021 Apr 16;taab064. doi:10.1093/jtm/taab064.
  • CNN Travel. China opens its borders to foreigners who take Chinese shots, as geopolitical vaccine silos emerge. [accessed 2021 April 12]. https://edition.cnn.com/travel/article/covid-vaccine-travel-visa-rules-intl-hnk/index.html
  • World Health Organization. Interim guidance for developing a smart vaccination certificate. [accessed 2021 April 12]. https://www.who.int/publications/m/item/interim-guidance-for-developing-a-smart-vaccination-certificate
  • Osama T, Razai MS, Majeed A. Covid-19 vaccine passports: access, equity, and ethics. BMJ. 2021 Apr 1;373:n861. doi:10.1136/bmj.n861. PMID: 33795260.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.